文献速递血栓与止血

皮下注射新一代凝血因子IX变体Dalcinonacog alfa在经治血友病B患者中的安全性、药代动力学和药效学研究

Safety, pharmacokinetics, and pharmacodynamics of a next-generation subcutaneously administered coagulation factor IX variant, dalcinonacog alfa, in previously treated hemophilia B patients.
PubMed 文献 · J Thromb Haemost · 2021-03-24

这项多中心1/2a期研究在11例12至65岁重型血友病B男性患者中评估了皮下注射Dalcinonacog alfa的安全性、药代动力学和药效学。结果显示DalcA效力比BeneFIX高24倍,皮下生物利用度为8.2%至20.3%,每日皮下给药6次后达到中位FIX活性15.7%。两例堂兄弟出现了针对ISU304的中和抗体,但未出现针对野生型FIX的中和抗体。

要点

  • DalcA效力比BeneFIX高24倍,平均驻留时间33.8小时。
  • 每日皮下注射150 IU/kg连续6天可达中位FIX活性15.7%。
  • 两例患者出现针对ISU304的中和抗体,但无针对野生型FIX的抗体。

核心结论

  • DalcA皮下给药可达到11%至18%的保护性FIX活性水平,对应降低自发性出血风险。

研究设计与样本

  • 多中心1/2a期研究(NCT03186677),纳入11例12至65岁重型血友病B男性患者,分为6个队列接受静脉或皮下DalcA及对照药BeneFIX。

主要发现

  • DalcA效力比BeneFIX高24倍,平均驻留时间33.8小时。
  • 皮下生物利用度8.2%至20.3%,β半衰期53.9至106.9小时,Tmax 24至48小时。
  • 每日皮下给药6次后达到中位FIX活性15.7%(四分位距14.9%-16.6%)。
  • 两例堂兄弟出现针对ISU304的中和抗体,但未出现针对野生型FIX的中和抗体。

关键数值与推荐

  • 皮下注射DalcA 75 IU/kg或150 IU/kg,每日给药。
  • 每日皮下150 IU/kg连续6天可达中位FIX活性15.7%。

临床怎么用

  • DalcA皮下给药有望用于血友病B的预防治疗,需关注抗药抗体产生。

局限性

  • 样本量小(11例),为早期研究,需进一步2b期试验验证安全性和疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dalcinonacog alfa (DalcA), a next-generation, recombinant human factor IX (FIX) variant, was developed using a rational design approach for increased procoagulant activity and longer duration of action to be administered subcutaneously (SC) for prophylaxis of hemophilia B bleeding episodes. OBJECTIVES: To investigate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of DalcA. METHODS: This multicenter, phase 1/2a study (NCT03186677) was conducted in 11 males aged 12 to 65 years with severe hemophilia B. In cohort 1, subjects received intravenous (IV) 75 IU/kg BeneFIX and DalcA. Cohorts 2 and 3 had DalcA IV 75 IU/kg and SC 75 IU/kg or 150 IU/kg. Cohort 4 was omitted. Cohort 5 received daily SC 150 IU/kg DalcA for 6 days and cohort 6 received IV 75 IU/kg and daily SC 150 IU/kg DalcA for 9 days. Blood sampling was performed for chemistry, hematology, PK, PD, and anti-drug antibody measurement. Subjects were monitored for safety endpoints for 30 days postdosing. RESULTS: DalcA demonstrated a 24-fold greater potency over BeneFIX and longer mean residence time (33.8 h). SC bioavailability 8.2% to 20.3%, beta half-life 53.9 to 106.9 h and Tmax 24 to 48 h. A median 15.7% FIX activity level (interquartile range, 14.9%-16.6%) was reached after 6 daily doses. Neutralizing antibodies to ISU304, but not wild-type FIX, occurred in two cousins. CONCLUSIONS: The data demonstrated that DalcA achieved protective FIX activity levels between 11% and 18%, corresponding to a reduced chance of spontaneous bleeds. Based on the results, a phase 2b trial to assess the safety and efficacy of 28 daily SC doses of DalcA was performed.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. You CW, Hong SB, Kim S, et al. Safety, pharmacokinetics, and pharmacodynamics of a next-generation subcutaneously administered coagulation factor IX variant, dalcinonacog alfa, in previously treated hemophilia B patients. J Thromb Haemost. 2021. PMID: 33540485. doi:10.1111/jth.15259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。